These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prevention of coronary heart disease: data in table 2 could be shown more explicitly for better understanding. Messori A; Santarlasci B BMJ; 2004 Feb; 328(7436):405; author reply 405. PubMed ID: 14962887 [No Abstract] [Full Text] [Related]
3. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Martens LL; Guibert R Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684 [TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels. Maclaine GD; Patel H Int J Clin Pract; 2001 May; 55(4):243-9. PubMed ID: 11406909 [TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of HMG-CoA reductase inhibition in Canada. Russell MW; Huse DM; Miller JD; Kraemer DF; Hartz SC Can J Clin Pharmacol; 2001; 8(1):9-16. PubMed ID: 11283756 [TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of statins for the secondary prevention of coronary heart disease in Ireland. Barry M; Heerey A Ir Med J; 2002 May; 95(5):133-5. PubMed ID: 12092692 [No Abstract] [Full Text] [Related]
8. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat? van Hout BA; Simoons ML Eur Heart J; 2001 May; 22(9):751-61. PubMed ID: 11350107 [TBL] [Abstract][Full Text] [Related]
9. Statins for cardiovascular prevention according to different strategies: a cost analysis. Ito MK; Nanchen D; Rodondi N; Paccaud F; Waeber G; Vollenweider P; Marques-Vidal P Am J Cardiovasc Drugs; 2011; 11(1):33-44. PubMed ID: 21265581 [TBL] [Abstract][Full Text] [Related]
10. Pravastatin and coronary heart disease. Bloom JM N Engl J Med; 1999 Apr; 340(14):1116-7. PubMed ID: 10206831 [No Abstract] [Full Text] [Related]
11. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease. Walshe V; Nash A; Barry M Ir Med J; 2006 May; 99(5):144-5. PubMed ID: 16892920 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of lipid-lowering treatment according to lipid level. Pilote L; Ho V; Lavoie F; Coupal L; Zowall H; Grover SA Can J Cardiol; 2005 Jun; 21(8):681-7. PubMed ID: 16003451 [TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of statins in coronary heart disease. Franco OH; Peeters A; Looman CW; Bonneux L J Epidemiol Community Health; 2005 Nov; 59(11):927-33. PubMed ID: 16234419 [TBL] [Abstract][Full Text] [Related]
15. [SBU should investigate what is an evidence-based and cost-effective use of statins]. Hjemdahl P; Allhammar A; Heaton C; Hulting J; Kahan T; Malmström R; Martinsson A; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B Lakartidningen; 2009 Aug 5-18; 106(32-33):1992-4. PubMed ID: 19764381 [No Abstract] [Full Text] [Related]
16. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. Hirsch M; O'Donnell JC; Jones P Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502 [TBL] [Abstract][Full Text] [Related]
17. [How far the rates of cholesterol have to be lowered in primary prevention?]. Rodondi N Rev Med Suisse; 2010 Mar; 6(239):483-4. PubMed ID: 20373693 [No Abstract] [Full Text] [Related]
18. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial). Miller PS; Smith DG; Jones P Am J Cardiol; 2005 Jun; 95(11):1314-9. PubMed ID: 15904635 [TBL] [Abstract][Full Text] [Related]
19. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis. Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264 [TBL] [Abstract][Full Text] [Related]
20. The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices. Plans-Rubió P Am J Cardiovasc Drugs; 2010; 10(6):369-82. PubMed ID: 21090830 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]